UCB Biosciences, Inc.
Clinical trials sponsored by UCB Biosciences, Inc., explained in plain language.
A subsidiary of UCB, a global biopharmaceutical company focused on neurology and immunology.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New hope for infants with severe epilepsy: fenfluramine trial launches
Disease control CompletedThis phase 3 trial is testing the safety and tolerability of fenfluramine (Fintepla) in 25 infants aged 1 to 2 years with Dravet syndrome, a severe form of epilepsy. The drug is given as an oral solution twice daily alongside other seizure medications. Researchers will monitor he…
Phase 3 • Sponsor: UCB BIOSCIENCES, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug cocktail shows promise for rare muscle disease
Disease control CompletedThis phase 2 study tests a combination of two nucleoside drugs, doxecitine and doxribtimine, in 47 people with thymidine kinase 2 (TK2) deficiency, a rare genetic disorder that weakens muscles. Participants already receiving nucleoside therapy continue treatment to see if the dru…
Phase 2 • Sponsor: UCB BIOSCIENCES, Inc. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Healthy volunteers help uncover drug interactions
Knowledge-focused CompletedThis study looked at how a medicine called ZX008 changes the way the body processes three other drugs (midazolam, bupropion, and metformin). Twenty-two healthy adults aged 18 to 55 took part. The goal was to measure drug levels in the blood, not to treat any disease.
Phase 1 • Sponsor: UCB BIOSCIENCES, Inc. • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC